Advertisement

Supplemental Material

The links to relevant recommendations of the American College of Obstetricians and Gynecologists are provided as the primary source of supplemental information to that provided in Clinical Updates in Women's Health Care monographs when applicable. The links to resources other than those of the American College of Obstetricians and Gynecologists are provided for information purposes only, and referral to these resources does not imply the endorsement of the American College of Obstetricians and Gynecologists.

[A]

Adverse Drug Reactions (Vol XIII, No 4)

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For clinical guidelines regarding thrombocytopenia in pregnancy, refer to Thrombocytopenia in pregnancy. Practice Bulletin No. 166. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e43-53.

For recommendations on statin use for the prevention of cardiovascular disease, refer to Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. U.S. Preventive Services Task Force. JAMA 2016;316:1997-2007.

Anemia (Vol XI, No 5)

For additional information on patients who refuse blood transfusion, refer to the following documents:

Gupta S, Onwude J, Stasi R, Manyonda I. Refusal of blood transfusion by Jehovah's Witness women: a survey of current management in obstetric and gynaecological practice in the UK. Blood Transfus 2012;10:462-70.

Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet 2013;381:1855-65.

Anorectal Disorders (Vol IX, No 1)

Anorectal Disorders, Supplement, Volume IX, Number 1, January 2010 (Reaffirmed 2016)

For clinical guidelines on the management of benign anorectal disorders from the American College of Gastroenterology, refer to Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG Clinical Guideline: management of benign anorectal disorders. Am J Gastroenterol 2014;109:1141-57.

Arrhythmias (Vol XVI, No 3)

For the latest ACC/AHA guidelines on the primary prevention of cardiovascular disease, involving lifestyle and behavioral factors, refer to Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Part 1, Lifestyle and Behavioral Factors. JAMA Cardiol. Published online July 31, 2019. doi:10.1001/jamacardio.2019.2604

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on screening for cardiovascular disease, refer to U.S. Preventive Services Task Force. Screening for cardiovascular disease risk with electrocardiography: U.S. Preventive Services Task Force recommendation statement. JAMA 2018;319:2308-14.

[C]

Common Dermatologic Conditions (Vol XVII, No 1)

For guidelines of care for the management of primary cutaneous melanoma, refer to Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2018;xx:xxx-xxx. DOI: 10.1016/j.jaad.2018.08.055. Available at: https://www.sciencedirect.com/science/article/pii/S019096221832588X. Retrieved November 1, 2018.

[E]

Evaluation and Management of Lipid Disorders (Vol XIII, No 2)

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

Exercise (Vol XII, No 2)

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For a resource from the CDC on CV disease prevention by exercise, refer to Omura JD, Carlson SA, Paul P, Watson KB, Loustalot F, Foltz JL, et al. Adults eligible for cardiovascular disease prevention counseling and participation in aerobic physical activity—United States, 2013. MMWR Morb Mortal Wkly Rep 2015;64:1047-51.

For new information regarding warnings and contraindications to exercise during pregnancy refer to Physical activity and exercise during pregnancy and the postpartum period. Committee Opinion No. 650. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e135-42.

For Dietary Guidelines for Americans 2015-2020 refer to http://health.gov/dietaryguidelines/2015/guidelines/

[G]

Gynecologic and Obstetric Care for Breast Cancer Survivors (Vol XVI, No 4)

For information regarding risk assessment, genetic counseling, and genetic testing for BRCA-related cancer, refer to US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2019;322:652-65.

For consensus guidelines on testing for hereditary breast cancer from the American Society of Breast Surgeons, refer to The American Society of Breast Surgeons. Consensus guideline on genetic testing for hereditary breast cancer. Columbia (MD): The American Society of Breast Surgeons; 2019. Available at: https://www.breastsurgeons.org/about/statements/PDF_Statements/Hereditary_
Genetic_Testing_Patients_With_Without_Breast_Cancer.pdf
. Retrieved March 6, 2019.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For ACOG guidelines on the use of aromatase inhibitors, refer to Aromatase inhibitors in gynecologic practice. ACOG Committee Opinion No. 738. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e194-9.

For information about management of genitourinary syndrome of menopause, refer to Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018;256:596-608.

For information about integrative therapies before and after breast cancer treatment, refer to Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, et al. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018:JCO2018792721.

For information on cardiovascular disease and breast cancer, refer to a scientific statement from the American Heart Association: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

For additional information on breast cancer risk assessment, refer to Breast cancer risk assessment and screening in average-risk women. Practice Bulletin No. 179. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e1-16.

For additional information on hereditary breast and ovarian cancer syndrome, refer to Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 182. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e110-26.

For additional information on hereditary cancer syndromes and risk assessment, refer to Hereditary cancer syndromes and risk assessment. Committee Opinion No. 634. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:1538-43.

For additional information on osteoporosis, refer to Osteoporosis. Practice Bulletin No. 129. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:718-34.

[H]

Hypertension (Vol XV, No 1)

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For information on emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period, refer to Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. ACOG Committee Opinion No. 767. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e174-80.

For information on chronic hypertension in pregnancy, refer to Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e26-50.

For information on gestational hypertension and preeclampsia, refer to Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 202. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e1-25.

For additional information on severe hypertension, refer to Bernstein PS, Martin JN Jr, Barton JR, Shields LE, Druzin ML, Scavone BM, et al. National Partnership for Maternal Safety: consensus bundle on severe hypertension during pregnancy and the postpartum period. Obstet Gynecol 2017;130:347-57.

For 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) refer to: http://jama.jamanetwork.com/article.aspx?articleid=1791497

For information on hypertension-related mortality in the United States in 2000-2013 refer to http://www.cdc.gov/nchs/data/databriefs/db193.htm

For additional information on preeclampsia, refer to First-trimester risk assessment for early-onset preeclampsia. Committee Opinion No. 638. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e25-7.

For the AGOG Practice Advisory on Low-Dose Aspirin and Prevention of Preeclampsia, refer to http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Low-Dose-Aspirin-and-Prevention-of-Preeclampsia-Updated-Recommendations

[I]

Ischemic Heart Disease (Vol XVI, No 6)

For the latest ACC/AHA guidelines on the primary prevention of cardiovascular disease, involving lifestyle and behavioral factors, refer to Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Part 1, Lifestyle and Behavioral Factors. JAMA Cardiol. Published online July 31, 2019. doi:10.1001/jamacardio.2019.2604

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For information on screening for cardiovascular disease, refer to U.S. Preventive Services Task Force. Screening for cardiovascular disease risk with electrocardiography: U.S. Preventive Services Task Force recommendation statement. JAMA 2018;319:2308-14.

[L]

Liver Disease: General Pathophysiology, Diagnosis, and Management (Vol XV, No 6)

Liver Disease: General Pathophysiology, Diagnosis, and Management, Supplement, Volume XV, Number 6, November 2016

Liver Disease: Reproductive Considerations (Vol XVI, No 1)

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For ACOG guidelines on HPV vaccinations, refer to Human papillomavirus vaccination. Committee Opinion No. 704. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e173-8.

Below is the current list of guidelines developed by the American College of Obstetricians and Gynecologists that relate to various aspects of liver disease in reproductive-aged and postmenopausal women:

Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 189. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e15-30.

American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.

Viral hepatitis in pregnancy. ACOG Practice Bulletin No. 86. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:941-56.

Cervical cancer screening and prevention. Practice Bulletin No. 168. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e111-30.

Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No. 128. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:197-206.

Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No. 110. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;115:206-18.

Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:202-16.

Osteoporosis. Practice Bulletin No. 129. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:718-34.

[M]

Metabolic Bone Disease (Vol XIV, No 2)

For a resource from the NIH on vitamin D supplementation refer to Fact Sheet for Health Professionals: Vitamin D

For information on dietary reference intakes for calcium and vitamin D refer to: https://iom.nationalacademies.org/~/media/Files/ReportFiles/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin D and Calcium 2010 Report Brief.pdf

For Dietary Guidelines for Americans 2015-2020 refer to http://health.gov/dietaryguidelines/2015/guidelines/

For recommendations regarding aromatase inhibitors in GYN practice, refer to Aromatase inhibitors in gynecologic practice. Committee Opinion No. 663. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e170-4.

Mood and Anxiety Disorders (Vol XVI, No 5)

For information regarding assessment and management of patients at risk for suicide, refer to Sall J, Brenner L, Bell AM, Colston MJ. Assessment and management of patients at risk for suicide: synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines. Ann Intern Med 2019;171:343-53.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For guidelines for the evaluation and treatment of perimenopausal depression, refer to Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Menopause 2018;1069-85.

For additional information on mental health disorders in adolescents, refer to Mental health disorders in adolescents. Committee Opinion No. 705. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e32-41.

For a compilation of resources on mental health disorders in adolescents, refer to https://www.acog.org/Womens-Health/Mental-Health-Disorders-in-Adolescents.

For additional information on screening for perinatal depression, refer to Screening for perinatal depression. ACOG Committee Opinion No. 757. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e208-12.

For additional information on the use of psychiatric medications during pregnancy and lactation, refer to Use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin No. 92. American College of Obstetricians and Gynecologists. Obstet Gynecol 2008;111:1001-20.

For additional information on noncontraceptive uses of hormonal contraceptives, refer to Noncontraceptive uses of hormonal contraceptives. Practice Bulletin No. 110. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;115:206-18.

For additional resources on depression and postpartum depression, refer to https://www.acog.org/Womens-Health/Depression-and-Postpartum-Depression.

For a compilation of web sites related to depression and postpartum depression, refer to https://www.acog.org/About-ACOG/ACOG-Departments/Resource-Center/WEBTREATS-Depression-Resources.

For information on opioid use and opioid use disorder in pregnancy, refer to Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e81-94.

[N]

Nutrition (Vol XIII, No 3)

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on listeria refer to: Management of pregnant women with presumptive exposure to Listeria monocytogenes. Committee Opinion No. 614. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;124:1241-4.

For a resource from the NIH on vitamin D supplementation refer to Fact Sheet for Health Professionals: Vitamin D

For information on dietary reference intakes for calcium and vitamin D refer to: https://iom.nationalacademies.org/~/media/Files/ReportFiles/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin D and Calcium 2010 Report Brief.pdf

For new information regarding warnings and contraindications to exercise during pregnancy refer to Physical activity and exercise during pregnancy and the postpartum period. Committee Opinion No. 650. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e135-42.

For Dietary Guidelines for Americans 2015-2020 refer to http://health.gov/dietaryguidelines/2015/guidelines/

For information on seafood consumption during pregnancy, refer to the ACOG Practice Advisory: Update on Seafood Consumption During Pregnancy at http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/ACOG-Practice-Advisory-Seafood-Consumption-During-Pregnancy

[O]

Obesity (Vol XII, No 1)

For information regarding gynecologic surgery in the obese patient, refer to Yong PJ, Thurston J, Singh SS, Allaire C. Guideline No. 386-Gynaecologic surgery in the obese patient. J Obstet Gynaecol Can 2019;41:1356-70.e7.

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For recommendations regarding behavioral weight loss interventions, refer to U.S. Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults. U.S. Preventive Services Task Force recommendation statement. JAMA 2018;320:1163-71.

For information on ethical issues in the care of the obese woman refer to: Ethical Issues in the Care of the Obese Woman. Committee Opinion No. 600. American College of Obstetricians and Gynecologists.

For The Obesity Society, American College of Cardiology, and American Heart Association guidelines on management of obesity, go to Guidelines (2013) for Managing Overweight and Obesity in Adults

For information on gynecologic surgery in the obese woman refer to: Gynecologic surgery in the obese woman. Committee Opinion No. 619. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:274-8.

For new information on obesity in pregnancy refer to Obesity in pregnancy. Practice Bulletin No. 156. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e112-26.

For new information regarding warnings and contraindications to exercise during pregnancy refer to Physical activity and exercise during pregnancy and the postpartum period. Committee Opinion No. 650. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e135-42.

For Dietary Guidelines for Americans 2015-2020 refer to http://health.gov/dietaryguidelines/2015/guidelines/

For current prepregnancy BMI data from the Centers for Disease Control and Prevention, refer to Prepregnancy Body Mass Index by Maternal Characteristics and State: Data From the Birth Certificate, 2014.

For a position statement on adolescent obesity from the Society for Adolescent Health and Medicine, refer to Society for Adolescent Health and Medicine. Preventing and treating adolescent obesity: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health 2016;59:602-6.

Occupational Diseases and Injuries (Vol IX, No 3)

For related information on exposure to toxic environmental agents refer to:

http://www.acog.org/Resources_And_Publications/Committee_Opinions
/Committee_on_Health_Care_for_Underserved_Women
/Exposure_to_Toxic_Environmental_Agents


http://www.acog.org/About_ACOG/ACOG_Departments/Health_Care_for_Underserved_
Women/~/media/Committee%20Opinions/Committee%20on%20Health%20Care%20for
%20Underserved%20Women/ExposuretoToxic.pdf

[P]

Perioperative Pain Management (Vol XVII, No 6)

Perioperative pathways: enhanced recovery after surgery. ACOG Committee Opinion No. 750. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e120-30.

For additional information on obstetric analgesia and anesthesia, refer to Obstetric analgesia and anesthesia. ACOG Practice Bulletin No. 209. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e208-25.

Polycystic Ovary Syndrome (Vol XV, No 4)

For ACOG guidelines on polycystic ovary syndrome, refer to Polycystic ovary syndrome. ACOG Practice Bulletin No. 194. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e157-71.

For the latest resources on evaluation, management, and health care needs, of patients with polycystic ovary syndrome, refer to the Centre for Research Excellence in Polycystic Ovary Syndrome.

[S]

Sexuality and Sexual Disorders (Vol XIII, No 2)

For ACOG guidelines on the use of aromatase inhibitors, refer to Aromatase inhibitors in gynecologic practice. ACOG Committee Opinion No. 738. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e194-9.

For additional information on sexual health, refer to Sexual health. Committee Opinion No. 706. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e42-7.

For information on testosterone therapy in female sexual dysfunction refer to: Androgen Therapy: A Reappraisal: An Endocrine Society Clinical Practice Guideline.

For information on sexuality education, refer to Comprehensive sexuality education. Committee Opinion No. 678. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e227-30.

For a compilation of resources on sex and sexuality prepared by the ACOG Resource Center, refer to http://www.acog.org/About_ACOG/ACOG_Departments
/Resource_Center/WEBTREATS_Sex_and_Sexuality

Sleep Disorders (Vol XI, No 3)

For current patient information from the American Sleep Apnea Association, refer to http://sleepapnea.org/index.html

Structural Heart Disease (Vol XVI, No 2)

For the latest ACC/AHA guidelines on the primary prevention of cardiovascular disease, involving lifestyle and behavioral factors, refer to Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Part 1, Lifestyle and Behavioral Factors. JAMA Cardiol. Published online July 31, 2019. doi:10.1001/jamacardio.2019.2604

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

Surgical Considerations (Vol XVIII, No 1)

For information regarding gynecologic surgery in the obese patient, refer to Yong PJ, Thurston J, Singh SS, Allaire C. Guideline No. 386-Gynaecologic surgery in the obese patient. J Obstet Gynaecol Can 2019;41:1356-70.e7.

[T]

Thrombosis, Thrombophilia, and Thromboembolism (Vol XV, No 3)

For the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease, refer to Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease [preprint]. Circulation 2019;DOI: 10.1161/CIR.0000000000000678. Available at: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Retrieved March 21, 2019.

For information on thrombocytopenia in pregnancy, refer to Thrombocytopenia in pregnancy. ACOG Practice Bulletin No. 207. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e181-93.

For information on the use of hormonal contraception in women with coexisting medical conditions, refer to Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:e128-50.

For information regarding inherited thrombophilias in pregnancy, refer to Inherited thrombophilias in pregnancy. Practice Bulletin No. 138 American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122:706-17.

Thyroid Disorders (Vol XII, No 5)

For information regarding thyroid disease in pregnancy refer to Thyroid disease in pregnancy. Practice Bulletin No. 148. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015; 125:996 -1005.

[U]

Upper Gastrointestinal Tract, Biliary, and Pancreatic Disorders (Vol XI, No 4)

For additional information on nausea and vomiting during pregnancy, refer to Nausea and vomiting of pregnancy. ACOG Practice Bulletin No. 189. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e15-30.

For the National Institute for Health and Care Excellence guidelines for cancer recognition and referral go to http://www.nice.org.uk/guidance/NG12/chapter/1-recommendations.

 




Editor
Russell R. Snyder, MD

Associate Editor
Anne E. Burke, MD

ISSN 1536-3619
Published 6 times per year